<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002936</url>
  </required_header>
  <id_info>
    <org_study_id>2012004</org_study_id>
    <nct_id>NCT02002936</nct_id>
  </id_info>
  <brief_title>Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study</brief_title>
  <official_title>Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SymBio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SymBio Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This is an extension study to investigate long term safety and efficacy of SyB C-1101 when&#xD;
      orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who&#xD;
      have completed 6 cycles in the study 2012002 whose purpose is to investigate tolerability of&#xD;
      SyB C-1101 when administered orally in patients with recurrent/relapsed or refractory&#xD;
      myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Total number affected by any adverse events (details are presented in adverse event section)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Efficacy in Hematologic Remission (IWG2006 Criteria)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>SD (stable disease): according to International Working Group 2006 response criteria for myelodysplastic syndrome, SD was defined as a failure to achieve &quot;complete remission&quot; or &quot;partial remission,&quot; but no evidence of progression for &gt; 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>NCA (not considered assessable): no evidence of HI-E (hematologic improvement-erythroid), HI-P (hematologic improvement-platelet), HI-N (hematologic improvement-neutorophil), progressive disease, or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic Response Ratio According to IWG 2006 Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>NCA (not considered assessable): no cytogenetic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Survived</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Laboratory Test Results</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Clinically significant changes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>SyB C-1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SyB C-1101</intervention_name>
    <description>SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.&#xD;
The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).&#xD;
From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.</description>
    <arm_group_label>SyB C-1101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must satisfy the following conditions listed below.&#xD;
&#xD;
          1. Patients enrolled in the study 2012002 of SyB C-1101 in Patients With Myelodysplastic&#xD;
             Syndrome.&#xD;
&#xD;
          2. Patients who were not judged as disease progression* nor progressive disease/relapse**&#xD;
             at the end of the cycle 6 in the study 2012002. * hematologic remission according to&#xD;
             IWG 2006 criteria ** hematologic improvement according to IWG 2006 criteria&#xD;
&#xD;
          3. Patients who met the continuation criteria*** after Cycle 6 week 3 (Day 22±3) in the&#xD;
             study 2012002.&#xD;
&#xD;
             ***defined in the study 2012002 protocol &quot;4.5 Criteria for Transition to the Next&#xD;
             Cycle &quot;&#xD;
&#xD;
          4. Patients who can be expected to survive at least three months or longer.&#xD;
&#xD;
          5. Patients who have score of 0 to 2 in Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Status (PS).&#xD;
&#xD;
          6. Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.).&#xD;
&#xD;
               -  Aspartate aminotransferase (AST): no more than 3.0 times the upper boundary of&#xD;
                  the reference range at each institution&#xD;
&#xD;
               -  Alanine aminotransferase (ALT): no more than 3.0 times the upper boundary of the&#xD;
                  reference range at each institution&#xD;
&#xD;
               -  Total bilirubin: no more than 1.5 times the upper boundary of the reference range&#xD;
                  at each institution&#xD;
&#xD;
               -  Serum creatinine: no more than 1.5 times the upper boundary of the reference&#xD;
                  range at each institution&#xD;
&#xD;
               -  ECG: no abnormal findings requiring treatment&#xD;
&#xD;
               -  Echocardiography: no abnormal findings requiring treatment&#xD;
&#xD;
          7. Patients who personally signed an informed consent document for participation in this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who satisfy any of the following conditions after Cycle 6 week 3 (Day 22±3) in the&#xD;
        study 2012002 will not be enrolled in the study.&#xD;
&#xD;
          1. Patients with anemia caused by factors other than MDS(hemolytic anemia,&#xD;
             gastrointestinal hemorrhage, etc.).&#xD;
&#xD;
          2. Patients with obvious infectious diseases (including viral infections).&#xD;
&#xD;
          3. Patients with serious complications (liver failure, renal failure, etc.).&#xD;
&#xD;
          4. Patients with a complication of serious heart disease (myocardial infarction, ischemic&#xD;
             heart disease, etc.)&#xD;
&#xD;
          5. Patients with a serious gastrointestinal condition (severe or significant&#xD;
             nausea/vomiting, diarrhea, etc.)&#xD;
&#xD;
          6. Patients with serious bleeding tendencies (disseminated intravascular coagulation&#xD;
             (DIC), internal hemorrhage, etc.).&#xD;
&#xD;
          7. Ascites or pleural fluid requiring active medical management including paracentesis,&#xD;
             or hyponatremia (defined as serum sodium value of &lt; 130 mEq/L).&#xD;
&#xD;
          8. Patients with known allergy to polyethylene glycol or gelatin capsules.&#xD;
&#xD;
          9. Patients with an addiction to a legal or illegal drug, or with alcohol dependency.&#xD;
&#xD;
         10. Patients who are nursing, pregnant or may become pregnant, or lactating mothers.&#xD;
&#xD;
         11. Patients who have not consented to the following contraceptive measures. Patients will&#xD;
             avoid sexual intercourse with sexual partners or should use the following&#xD;
             contraceptive methods in these time periods: for male patients during the&#xD;
             administration period of the trial and for six months after the end of administration;&#xD;
             female patients during the administration period of the trial and until a second&#xD;
             menstrual period is confirmed after the end of administration (or in the case of&#xD;
             female patients with no menstrual period, for two months after the end of&#xD;
             administration). 1) Male patients: Patients will always use a condom.&#xD;
&#xD;
             For effective contraception, it is recommended that the female partner also use the&#xD;
             contraceptive methods for female patients. 2) Female patients: Female patients who may&#xD;
             become pregnant should use one or more types of the following contraceptive methods.&#xD;
             In addition, the male partner will always use a condom.&#xD;
&#xD;
               -  Oral contraceptive (birth control pills)&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Tubal ligation&#xD;
&#xD;
         12. Other patients judged to be unsuitable by an investigator or sub-investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsuhisa Goto</last_name>
    <role>Study Director</role>
    <affiliation>SymBio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SyB C-1101</title>
          <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SyB C-1101</title>
          <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Total number affected by any adverse events (details are presented in adverse event section)</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SyB C-1101</title>
            <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Total number affected by any adverse events (details are presented in adverse event section)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Efficacy in Hematologic Remission (IWG2006 Criteria)</title>
        <description>SD (stable disease): according to International Working Group 2006 response criteria for myelodysplastic syndrome, SD was defined as a failure to achieve &quot;complete remission&quot; or &quot;partial remission,&quot; but no evidence of progression for &gt; 8 weeks.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SyB C-1101</title>
            <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Efficacy in Hematologic Remission (IWG2006 Criteria)</title>
          <description>SD (stable disease): according to International Working Group 2006 response criteria for myelodysplastic syndrome, SD was defined as a failure to achieve &quot;complete remission&quot; or &quot;partial remission,&quot; but no evidence of progression for &gt; 8 weeks.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria.</title>
        <description>NCA (not considered assessable): no evidence of HI-E (hematologic improvement-erythroid), HI-P (hematologic improvement-platelet), HI-N (hematologic improvement-neutorophil), progressive disease, or relapse.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SyB C-1101</title>
            <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Efficacy in Hematologic Improvement Ratio According to IWG 2006 Criteria.</title>
          <description>NCA (not considered assessable): no evidence of HI-E (hematologic improvement-erythroid), HI-P (hematologic improvement-platelet), HI-N (hematologic improvement-neutorophil), progressive disease, or relapse.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytogenetic Response Ratio According to IWG 2006 Criteria</title>
        <description>NCA (not considered assessable): no cytogenetic response</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SyB C-1101</title>
            <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
          </group>
        </group_list>
        <measure>
          <title>Cytogenetic Response Ratio According to IWG 2006 Criteria</title>
          <description>NCA (not considered assessable): no cytogenetic response</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Survived</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SyB C-1101</title>
            <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survived</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Laboratory Test Results</title>
        <description>Clinically significant changes</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SyB C-1101</title>
            <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Laboratory Test Results</title>
          <description>Clinically significant changes</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SyB C-1101</title>
          <description>SyB C-1101 （rigosertib sodium）:&#xD;
Following Cycle 6 of Study 2012002, the treatment in this study was initiated. One cycle was defined as a 21-day cycle; 14-day oral administration of SyB C-1101 twice daily (Days 1 to 14) followed by a 1-week observation period (Days 15 to 21). The starting dose of SyB C-1101 in this study (Cycle 7) was the same as that was determined for the next cycle in Cycle 6 of Study 2012002.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katsuhisa Goto</name_or_title>
      <organization>SymBio Pharmaceuticals</organization>
      <phone>+81-3-5472-1127</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

